Article

Newly formed company to develop urology drugs

Yamanouchi Pharmaceutical Co., Ltd., and Fujisawa Pharmaceutical Co., Ltd., merged to form a new corporation named Astellas Pharma, Inc.

Yamanouchi Pharmaceutical Co., Ltd., and Fujisawa Pharmaceutical Co., Ltd., merged to form a new corporation named Astellas Pharma, Inc. The company said its focus will be on developing breakthrough products in various areas, including urology. The company will continue to support such drugs as solifenacin succinate (Vesicare) for the treatment of overactive bladder, tamsulosin hydrochloride (Flomax) for the treatment of BPH, and tacrolimus (Prograf) for the prevention of the treatment of organ rejection after liver and kidney transplants.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Brendan Frainey, MD, on microbiome composition in patients with spina bifida
Brendan Frainey, MD, on microbiome composition in patients with spina bifida
Dr. Rosalia Misseri on using long-term data to enhance pediatric urologic care
Dr. Rosalia Misseri on using long-term data to enhance pediatric urologic care
Dr. Saraf on testicular tissue cryopreservation for pediatric patients with cancer
Dr. Saraf on testicular tissue cryopreservation for pediatric patients with cancer
Study finds overtreatment of presumed UTI in pediatric patients with spina bifida
Study finds overtreatment of presumed UTI in pediatric patients with spina bifida
Miriam Harel, MD, answers questions during a Zoom video interview
Dr. Harel on hot topics in pediatric urology
Sleeping child | Image Credit: © Kenishirotie - stock.adobe.com
Pediatric urologist shares management strategies for nocturnal enuresis
Miriam Harel, MD, answers a question during a Zoom video interview
Dr. Harel on potential causes of nocturnal enuresis
Oral testosterone undecanoate shows promising results for first use in the real world
Oral testosterone undecanoate shows promising results for first use in the real world
Related Content
FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1
February 5th 2025

FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1

Hannah Clarke
A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.
Speaking of Urology: Dr. Finkelstein discusses telemedicine for pediatric post-op visits
September 8th 2020

Speaking of Urology: Dr. Finkelstein discusses telemedicine for pediatric post-op visits

Urology Times staff
In this episode, Julia Beth Finkelstein, MD, MPH, CPPS, discusses what she and her co-authors learned from a recent study evaluating the use of telemedicine for pediatric post-op visits.
Pediatric urinary microbiome composition is associated with recurrent UTI
September 10th 2024

Pediatric urinary microbiome composition is associated with recurrent UTI

Hannah Clarke
“We hope to learn more about the urinary tract and then be able to correlate predisposition to UTIs or other urological conditions with urobiome composition or marker microbe presence,” says Tatyana A. Sysoeva, PhD.
Amanda J. Saraf, DO, shares ongoing research on oncofertility options for pediatric patients
August 17th 2024

Amanda J. Saraf, DO, shares ongoing research on oncofertility options for pediatric patients

Urology Times staff
"But here at IU, we have an experimental protocol that's open that's called testicular tissue cryopreservation, and it's a collaboration with UPMC," says Amanda J. Saraf, DO.
ER utilization and overtreatment for UTI in pediatric patients with spina bifida
July 16th 2024

ER utilization and overtreatment for UTI in pediatric patients with spina bifida

Urology Times staff
"We've been working with families and other providers to learn the diagnostic criteria for what makes a urinary tract infection and to avoid treating when it's unnecessary," says Briony K. Varda, MD, MPH.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
February 15th 2024

Dr. Laurence Baskin discusses robotic pediatric urological surgery at UCSF

Laurence Baskin, MD
"Robotic surgery has some major advantages. One that rises to the top is that your magnification is anywhere from 10x-15x higher," according to Laurence S. Baskin, MD.
© 2025 MJH Life Sciences

All rights reserved.